Gut flora and weight management
The present invention relates to supporting weight management, weight loss and/or to the prevention and/or treatment of metabolic disorders. In particular the present invention relates to preventing and/or treating metabolic disorders by modulating, in particular reducing the amount of proteobacteria and/or deferribacteres in the gut. One embodiment of the present invention relates to the use of a primary composition comprising an agent that reduces the amount of proteobacteria, preferably gamma-proteobacteria, even more preferred enterobacteria; and/or deferribacteres in the gut for the preparation of a composition to treat or prevent metabolic disorders, to support weight loss and/or to support weight management.
1. A method to treat a metabolic disorder, to support weight loss and/or to support weight management comprising the step of administering to a patient in need of same a composition comprising an effective amount of an an agent that reduces the amount of at least one bacteria selected from the group consisting of proteobacteria and deferribacteres in the gut of the patient such that a ratio of proteobacteria to bacteriodetes in the gut is reduced to a range from 0 to 0.03, wherein the agent comprises an isolated culture of Lactobacillus rhamnosus CGMCC 1.3724.
2. The method in accordance with claim 1 , wherein the agent increases a ratio of proteobacteria to firmicutes in the gut to a range from 0.05 to 2.
3. The method in accordance with claim 1 , wherein the agent increases a ratio of bacteriodetes to firmicutes in the gut to a range from 1.5 to 30.
4. The method in accordance with claim 1 , wherein the patient suffers from a disorder selected from the group consisting of obesity, insulin resistance, type-2 diabetes, hyperglycemia, hepatic steatosis, and weight gain.
5. The method in accordance with claim 1 , wherein the composition is selected from the group consisting of a medicament and a food product.
6. The method in accordance with claim 1 , wherein the patient is selected from the group consisting of infants, children, adolescents and adults.
7. The method in accordance with claim 1 , wherein the composition comprises at least one range selected from the group consisting of between 10 2 and 10 12 cells of the Lactobacillus rhamnosus CGMCC 1.3724 per g of the dry weight of the composition, and between 10 2 and 10 12 cfu of the Lactobacillus rhamnosus CGMCC 1.3724 per g of the dry weight of the composition.
8. The method in accordance with claim 1 , wherein the composition is a food product selected from the group consisting of milk-powder based products; instant drinks; ready-to-drink formulations; nutritional powders; milk-based products, cereal products; beverages; water; coffee; cappuccino; malt drinks; chocolate flavoured drinks; culinary products and soups.
9. The method of claim 1 , wherein the bacteria is selected from the group consisting of gamma-proteobacteria and enterobacteria.
10. The method of claim 1 , wherein the patient is selected from the group consisting of humans, pets, and livestock.
11. The method in accordance with claim 1 , wherein the agent reduces a ratio of gamma-proteobacteria to bacteriodetes in the gut to a range from 0 to 0.03.
12. The method in accordance with claim 1 , wherein the agent increases a ratio of gamma-proteobacteria to firmicutes in the gut to a range from 0.5 to 2.
13. The method in accordance with claim 1 , wherein the agent reduces an amount of enterobacteria relative to a total amount of bacteria in the gut by 75-100% based on cfu.
14. The method in accordance with claim 1 , wherein administration of the composition treats a metabolic disorder and maintains a total body weight of the patient.
15. The method in accordance with claim 1 , wherein the Lactobacillus rhamnosus CGMCC 1.3724 within the composition is administered to the patient in an amount selected from the group consisting of 10 4 -10 12 cfu per day and 10 4 -10 12 cells per day.
16. The method in accordance with claim 1 , wherein the Lactobacillus rhamnosus CGMCC 1.3724 within the composition is administered to the patient in an amount selected from the group consisting of 10 9 -10 10 cfu per day and 10 9 -10 10 cells per day.
17. A method for treating a disorder selected from the group consisting of obesity, insulin resistance, type-2 diabetes, hyperglycemia, hepatic steatosis, and weight gain comprising the step of administering to a patient having same a composition comprising an effective amount of an an agent that reduces the amount of at least one bacteria selected from the group consisting of proteobacteria and deferribacteres in the gut of the patient such that a ratio of proteobacteria to bacteriodetes in the gut is reduced to a range from 0 to 0.03, wherein the agent comprises an isolated culture of Lactobacillus rhamnosus CGMCC 1.3724.